Abzena invests in expansion of biotherapeutics and makes executive appointment

07-Nov-2018 - Dr. Jonathan Goldman, CEO, announced that Abzena has augmented existing 500 L scale biologics equipment with $20M of investment into two new manufacturing suites at 500 L and 2000 L scale in a new GMP facility in San Diego, which will be equipped with Sartorius single use bioreactors. Abzena’s ...

Abzena takes on new facilities

09-Jan-2018 - Abzena plc enables the development and manufacture of biopharmaceutical products,provides an update on its UK and US facilities. In Cambridge, UK, the Group’s lease has commenced for 30,000 square feet of space in Building 900 on the Babraham Research Campus, as first announced in February 2015. ...

Acquisition of PacificGMP by Abzena

Abzena has acquired PacificGMP

15-Sep-2015 - The acquisition of PacificGMP is in line with Abzena’s strategy to expand its offering and provides the opportunity to capture more value through broader support for its partners’ development projects and enables cross-selling of its services and technologies. The acquisition is expected to ...

Abzena subsidiary Antitope, INSERM and Baylor Institute for Immunology Research to collaborate to produce manufacturing cell lines for two vaccines for HIV

14-Jan-2015 - Abzena plc announced its wholly-owned subsidiary Antitope Limited has extended its relationship with INSERM, ANRS and the Baylor Institute for Immunology Research (“BIIR”.INSERM-ANRS and the BIIR have developed innovative approaches for HIV vaccines targeting HIV antigens to dendritic cells (DC) ...

Antitope and Synthon announce collaboration

04-Jul-2014 - Antitope Limited, an Abzena company, announced that it will collaborate with Synthon Biopharmaceuticals BV, to assess the potential immunogenicity of candidate antibodies for Synthon’s ADC programmes.Antitope will use its EpiScreen™ technology, a highly accurate and sensitive ex vivo human T ...

Antitope and Baylor Institute for Immunology Research to Collaborate on Cell Line for Novel Therapeutic Dendritic-cell-targeting Vaccine

11-Jun-2014 - Antitope Limited, an Abzena company, announced that it will develop a manufacturing cell line for the Baylor Institute for Immunology Research (“BIIR” using its Composite CHO™ technology. BIIR is developing a range of therapeutic vaccines for the treatment of cancer and other diseases, and ...

PolyTherics and Alpha Cancer Technologies Collaborate to Produce Drug Conjugates to Target Tumours

03-Jun-2014 - PolyTherics Limited, an Abzena company, announced a collaboration with Alpha Cancer Technologies Inc. (“ACT”. PolyTherics will produce a range of AFP drug conjugates for ACT to test using its proprietary ThioBridge™ technology.ACT has developed a drug delivery system based on AFP, a shuttle ...

PolyTherics and Antitope form Abzena

27-May-2014 - PolyTherics Limited announced the formation of a new company, Abzena Limited. The new company has been created to provide a strong group identity across its two wholly owned subsidiaries, PolyTherics and Antitope, following their combination in July 2013. During the summer PolyTherics’ operations ...